Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.
…
continue reading
1
Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis
1:05:29
1:05:29
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:05:29
Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go! Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of…
…
continue reading
1
Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics
1:04:37
1:04:37
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:04:37
Today I am talking to Eliot Forster xCEO of F-star Therapeutics. Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS. Prior to F-star, Eliot was CEO of Immu…
…
continue reading
1
Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.
1:45:49
1:45:49
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:45:49
Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discus…
…
continue reading
1
Episode 31: A Between the Biotech Waves Conversation with Tim Yu
55:34
55:34
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
55:34
Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 …
…
continue reading
1
Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics
45:57
45:57
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
45:57
Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Mille…
…
continue reading
1
Episode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real Estate
53:19
53:19
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
53:19
Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and the…
…
continue reading
1
Episode 28 A Between the Biotech Waves Conversation with Rachel Meyers
57:39
57:39
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
57:39
Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreci…
…
continue reading
1
Episode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of Synlogic
1:06:59
1:06:59
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:06:59
Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen…
…
continue reading
1
Episode 26: A Between the Biotech Waves conversation with Drew Weissman
57:08
57:08
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
57:08
Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivot…
…
continue reading
1
Episode 25: A Between the Biotech Waves conversation with Rodolphe Barrangou, the Todd R Klaenhammer Distinguished Professor at NC State University.
1:00:19
1:00:19
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:00:19
Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pio…
…
continue reading
1
Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking
56:51
56:51
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
56:51
I am delighted to welcome back Jim Birchenough to Between the Biotech Waves. Jim is Vice Chair Wells Fargo Biopharmaceutical Investment Banking. In 2022 Jim joined the podcast to discuss the market dynamics and learnings from prior market corrections. I am welcoming him back to take stock of where we are, what the bright spots in 2022 were and crys…
…
continue reading
1
Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
51:38
51:38
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
51:38
I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and many of his predictions were spot on. It was also one of the most downloaded podcasts of the year. I am welcom…
…
continue reading
1
A Between the Biotech Waves Conversation with Jeremy Levin, Chair & CEO of Ovid Therapeutics
1:11:32
1:11:32
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:11:32
Today we are talking to Jeremy Levin. Jeremy is chairman and CEO of Ovid Therapeutics, focused on rare and orphan disease of the CNS. He is the immediate past chair of BIO. Jeremy has a storied career in biotech having served as president and CEO of Teva Pharmaceutica’s, a member of the exec committee of BMS where he had global responsibilities for…
…
continue reading
1
Episode 21 A Between the Biotech Waves conversation with Laksh Aithani Co-founder & CEO of Charm Therapeutics
47:37
47:37
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
47:37
Today we are talking to Laksh Aithani, Co-founder and CEO of Charm Therapeutics. Laksh is a scientist turned entrepreneur. He received his degree in Natural Sciences from the University of Cambridge. While at University he co-founded Genei, an AI company that automatically summarizes background reading producing blogs, articles and reports (I would…
…
continue reading
1
Episode 20: A Between the Biotech Waves conversation with Tom Barnes, CEO of ORNA Therapeutics
53:50
53:50
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
53:50
Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millenni…
…
continue reading
1
Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder
50:11
50:11
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
50:11
Today we are talking to JeanFrancois Formela. I have known JF for over 2 decades having worked with him at Atlas in building multiple biotech companies. JF is a partner at Atlas Venture which he joined in 1993 to build the US LS presence which has ultimately become the Atlas we all know today. He co-founded, invested in and played pivotal roles in …
…
continue reading
1
Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
1:07:43
1:07:43
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:07:43
Today we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram was CBO and CFO of Corvidia, a company he successfully helped build and sell to Novo Nordisk for 2.1Bn$. P…
…
continue reading
1
Episode 17: A Between the Biotech Waves conversation with Regina Jorgensen, Director of the Maria Mitchell Observatory.
1:07:01
1:07:01
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:07:01
In this episode we discuss the formation and evolution of galaxies, our expanding universe, the big bang, the source of fast radio bursts, the James Webb Space Telescope and of course.....Aliens!โดย Nessan Bermingham PhD
…
continue reading
1
Episode 16: A Between the Biotech Waves conversation with Abraham Heifets CEO of Atomwise
1:00:18
1:00:18
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:00:18
Today we talk to Abe Heifets, CEO of Atomwise, a biotech company focusing on the utilization of AI for drug discovery. Atomwise recently (post this recording) announced a $1.2B discovery deal with Sanofi. We discuss AI, its use in drug discovery and development, recent advances and the potential sentient nature of AI. Enjoy.…
…
continue reading
1
Episode 15: A Between the Biotech Waves Conversation with Rodger Novak and Shaun Foy, co-founders with Emmanuelle Charpentier of CRISPR Therapeutics
1:07:22
1:07:22
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:07:22
Discussing the formation of CRISPR Tx, the positives, negatives and everything in between. This is the first time all three of us reconnected since our respective departures from our founding roles and features some candid moments from our respective journeys. Enjoy.โดย Nessan Bermingham PhD
…
continue reading
1
Episode 14: A Between the Biotech Waves Conversation with Paul Matteis, Managing Director of Biotechnology Equity Research at Stifel
1:00:57
1:00:57
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:00:57
โดย Nessan Bermingham PhD
…
continue reading
1
Episode 13: A Between the Biotech Waves Conversation with Vic Myer, President and CSO at Chroma Medicine
52:07
52:07
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
52:07
Today we talk to Vic Myer, xChief Technology Officer at Editas, currently President and CSO at Chroma Medicine. We discuss the state of genome editing and the potential for chromatin modification.โดย Nessan Bermingham PhD
…
continue reading
1
Episode 11: A Between the Biotech Waves conversation with Prof Robert Langer. In this episode we discuss nanoparticle delivery systems and the evolution of drug discovery.
51:13
51:13
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
51:13
โดย Nessan Bermingham PhD
…
continue reading
1
Episode 12: A Between the Biotech Waves conversation with Geoff Meacham, Managing Director of Equity Research at Banc of America covering Biotechnology and Major Pharmaceuticals in the US.
53:27
53:27
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
53:27
โดย Nessan Bermingham PhD
…
continue reading
1
Episode 9: A Between the Biotech Waves Conversation with Yaron Werber, MD of Healthcare Biotechnology at Cowen.
52:28
52:28
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
52:28
Today we are talking to Yaron Werber. Yaron is Managing Director of Healthcare Biotechnology at Cowen, he has over 20 years of experience as a research analyst and was a founding team member, chief business and financial officer of Ovid Therapeutics. Prior to Ovid Yaron was managing director and head of US healthcare and biotech equity research at …
…
continue reading
1
Episode 10: A Between the Biotech Waves Conversation with Eric Topol focusing on COVID & AI in healthcare
49:51
49:51
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
49:51
In this episode we are talking to Prof Eric Topol. Eric is a cardiologist by training, a basic scientist in the areas of personalized genomic medicine at the interface between genetics and digital health and is the author of the leading textbook in interventional cardiology in addition to authoring books on AI in medicine. He is the founder and dir…
…
continue reading
1
Episode 7 A conversation with John Hoffman Managing Director & head of Healthcare ECM at Credit Suisse
51:19
51:19
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
51:19
A Between the Biotech Waves conversation with John Hofffman, managing director & head of healthcare equity capital markets at Credit Suisse. John has nearly two decades of experience in supporting healthcare companies in the public markets. In this episode we discuss the current market dynamics from a equity capital market perspective.…
…
continue reading
1
Episode 8 John Leonard CEO of Intellia Therapeutics
49:54
49:54
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
49:54
A Between the Biotech Waves conversation with John Leonard, CEO of Intellia Therapeutics. John has over 30 years of experience in drug research & development. Prior to joining Intellia John was CSO at Abbvie. In this episode we discuss the formation of Intellia, some of the challenges and the recent data announced in ATTR.…
…
continue reading
1
A Between The Biotech Waves Conversation With William Hicks, Co-Chair of Securities & Capital Markets Mintz Levin
53:03
53:03
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
53:03
Today I talk to William Hicks, co-chair of securities and capital markets at Mintz Levin. We discuss the state of the capital markets, financing options for companies and the challenges companies face in this market.โดย Nessan Bermingham PhD
…
continue reading
1
A Between The Biotech Waves Conversation With Jim Birchenough, Vice Chair Wells Fargo Biopharmaceutical Investment Banking
41:08
41:08
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
41:08
A discussion of the current market volatility and options for public biotech companies with Jim Birchenough Vice Chair Wells Fargo Biopharmaceutical Investment Bankingโดย Nessan Bermingham
…
continue reading
1
A Between The Biotech Waves Conversation With Sumit Khedekar, Head of Healthcare of the Americas Investment Banking at Citi
51:51
51:51
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
51:51
A discussion of the current market volatility and options for public biotech companies with Sumit Khedekar, Head of Healthcare Investment Banking at Citiโดย Nessan Bermingham
…
continue reading
1
A Between The Waves Conversation with Julia Vitarello, the mother of Mila and co-developer of Milasen
1:05:02
1:05:02
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:05:02
A conversation with Julia Vitarello, founder of Mila's Miracle Foundation and co-founder of the N=1 Collaborative. Julia, in partnership with Dr Tim Yu, developed the first N of 1 genetic medicine to treat her daughter Milaโดย Nessan Bermingham
…
continue reading
1
A Between The Biotech Waves Conversation with Sek Kathiresan, founder & CEO of Verve Therapeutics
37:47
37:47
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
37:47
A Conversation With Sek Kathiresan MD, founder and CEO of Verve Therapeuticsโดย Nessan Bermingham
…
continue reading
1
A Between The Waves Conversation With Rich Ross, Technical Analyst at Evercore
39:32
39:32
เล่นในภายหลัง
เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
39:32
โดย Nessan
…
continue reading